UNSPSC 51171903: Nizatidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H21N5O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P41PML4GHR, chemically known as 1,1-ethenediamine, n-(2-(((2-((dimethylamino)methyl)-4-thiazoly)methyl)thio)ethyl)-n-methyl-2-nitro- but generally known as nizatidine, which bears US NIH Compound Identifier 3033637. European Medicines Agency schedules Nizatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09335MIG.

UNSPSC 51171903 Nizatidine, a Commodity code, represents pharmaceutical products procured by state and local health and criminal-justice agencies. State and local governments purchase nizatidine and similar histamine H2-receptor antagonists through direct commodity contracts with pharmaceutical manufacturers, cooperative purchasing vehicles, and as part of broader generic-pharmaceutical and over-the-counter product agreements. Issuing bodies range from state health departments and multistate cooperative purchasing alliances to county criminal-justice agencies and corrections departments. Recent solicitations show purchasing flowing through established wholesaler networks (AmerisourceBergen, Cardinal Health, Morris & Dickson) and standalone county procurement efforts.

Recent activity spans multiple states. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities for therapeutic pharmacy initiatives, signaling early-stage procurement planning rather than immediate competitive bidding. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026—this solicitation does not directly specify nizatidine but reflects the broader county-level pharmaceutical and testing procurement environment. Cooperative purchasing vehicles and state health agencies appear to drive the largest volume; county criminal-justice procurement is secondary.